Pre-Implantation Genetic Diagnosis (PGD / PGT) — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>Pre-Implantation Genetic Diagnosis (PGD) — now more precisely termed <strong>Preimplantation Genetic Testing (PGT)</strong> by the European Society of Human Reproduction and Embryology (ESHRE) — is an advanced reproductive technology performed in conjunction with In Vitro Fertilisation (IVF). Its core purpose is to screen embryos created outside the body for chromosomal abnormalities or specific genetic mutations <em>before</em> they are transferred to the uterus, thereby reducing the likelihood of miscarriage, failed implantation, or the birth of a child affected by a serious inherited disorder.</p><p>The procedure involves three major phases: controlled ovarian stimulation, fertilisation in the laboratory, and embryo biopsy for genetic analysis. During the biopsy — most commonly performed at the blastocyst stage (day 5–6) by sampling cells from the trophectoderm (the outer layer that becomes the placenta) — one to several cells are removed and subjected to molecular genetic analysis. The embryo remains in culture while results are processed, usually over 24–48 hours using next-generation sequencing (NGS), array comparative genomic hybridisation (aCGH), or polymerase chain reaction (PCR). Only embryos that pass the specified genetic criteria are selected for transfer.</p><p>PGT is divided into three internationally recognised subtypes: <strong>PGT-A</strong> (for aneuploidies — testing for correct chromosome number), <strong>PGT-M</strong> (for monogenic or single-gene disorders), and <strong>PGT-SR</strong> (for structural chromosomal rearrangements such as translocations or inversions). Each addresses a distinct clinical problem and is chosen based on a couple's specific genetic profile and reproductive history.</p><p>PGD/PGT does not replace standard prenatal diagnosis (such as amniocentesis or chorionic villus sampling), and most reproductive endocrinologists recommend confirmatory prenatal testing even after a successful PGT-M embryo transfer. It is not a guarantee of a healthy pregnancy or live birth, but it substantially reduces the probability of certain adverse outcomes and informs more confident embryo selection decisions.</p><p>Since the first successful clinical PGD case reported by Handyside et al. in 1990 (sexing embryos to avoid X-linked disorders), the technology has evolved dramatically. Modern NGS-based PGT-A can now analyse all 23 pairs of chromosomes simultaneously with high accuracy, and PGT-M workflows using Karyomapping or haplotyping can identify embryos affected by over 600 known monogenic conditions.</p>

<p>PGT encompasses a wide spectrum of genetic and chromosomal conditions that can be tested before embryo transfer. The three PGT subtypes address different categories:</p><h3>PGT-A: Chromosomal Aneuploidies</h3><p>Aneuploidy — having an abnormal number of chromosomes — is the leading cause of IVF failure and early miscarriage. PGT-A screens embryos for extra or missing chromosomes across all 23 pairs. Common aneuploidies detected include Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome), monosomy X (Turner syndrome), and Klinefelter syndrome (47,XXY). Most aneuploid embryos either fail to implant or result in early pregnancy loss, with a smaller proportion resulting in a livebirth with a chromosomal condition. PGT-A is particularly valuable for women of advanced maternal age (typically defined as 35 or older), in whom the rate of embryo aneuploidy rises sharply — from approximately 30% at age 35 to over 70% at age 42.</p><h3>PGT-M: Monogenic (Single-Gene) Disorders</h3><p>PGT-M is used when one or both partners carry a known pathogenic mutation in a specific gene. Conditions routinely tested include: <strong>autosomal recessive disorders</strong> such as cystic fibrosis (CFTR gene), spinal muscular atrophy (SMN1), sickle cell disease (HBB), beta-thalassaemia, and Tay-Sachs disease; <strong>autosomal dominant disorders</strong> such as Huntington's disease (HTT), BRCA1/BRCA2 mutations (hereditary breast-ovarian cancer syndrome), Marfan syndrome, myotonic dystrophy, and familial adenomatous polyposis; <strong>X-linked disorders</strong> such as Duchenne muscular dystrophy, haemophilia A and B, and fragile X syndrome. Each PGT-M test must be individually designed and validated for the specific mutation in the family — a process that typically takes 6–12 weeks before the IVF cycle begins.</p><h3>PGT-SR: Structural Chromosomal Rearrangements</h3><p>When one partner carries a balanced chromosomal translocation or inversion, their embryos are at risk of inheriting an unbalanced chromosomal complement, which typically results in recurrent miscarriage or a child with multiple congenital anomalies. PGT-SR identifies embryos that carry either a normal chromosomal complement or the same balanced rearrangement as the parent (both are clinically acceptable for transfer), distinguishing them from embryos with unbalanced rearrangements.</p><h3>HLA Matching (PGT-HLA)</h3><p>In families where an existing child is affected by a disorder treatable by haematopoietic stem cell transplantation (e.g., leukaemia, Fanconi anaemia, Diamond-Blackfan anaemia), PGT-HLA can be used to identify embryos that are both unaffected and HLA-compatible with the sick sibling, allowing the future child's cord blood to serve as a donor source. This application, sometimes called "saviour sibling" selection, is regulated differently across countries and requires careful ethical counselling.</p>

<p>PGT is considered for couples and individuals undergoing IVF who meet one or more of the following clinical criteria. A reproductive endocrinologist and clinical geneticist should jointly evaluate candidacy.</p><h3>Primary Indications</h3><ul><li><strong>Known carriers of a single-gene disorder:</strong> Couples where one or both partners are known carriers or are affected by an autosomal recessive, autosomal dominant, or X-linked genetic condition have a defined per-pregnancy risk of transmitting the disorder to their child. PGT-M reduces this risk to near zero for tested mutations.</li><li><strong>Chromosomal rearrangement carriers:</strong> Individuals with balanced translocations or inversions who have experienced recurrent pregnancy loss or difficulty conceiving are strong candidates for PGT-SR.</li><li><strong>Advanced maternal age (AMA):</strong> Women aged 35 and older, particularly those 38+, experience significantly higher rates of embryo aneuploidy. PGT-A helps identify euploid embryos for priority transfer, potentially improving cumulative live birth rates and reducing miscarriage.</li><li><strong>Recurrent implantation failure (RIF):</strong> Patients who have undergone three or more failed IVF cycles with good-quality embryos may benefit from PGT-A to exclude aneuploid embryos as a contributing cause.</li><li><strong>Recurrent pregnancy loss (RPL):</strong> Couples with two or more consecutive miscarriages, especially when chromosomal aneuploidy has been identified in products of conception.</li><li><strong>Severe male factor infertility:</strong> Men with very low sperm counts (severe oligozoospermia or azoospermia) have higher rates of de novo chromosomal abnormalities in sperm, increasing embryo aneuploidy rates.</li></ul><h3>Eligibility Requirements</h3><p>To be eligible for PGT, a patient must: (1) be undergoing an IVF cycle (PGT cannot be done on naturally conceived embryos without cryopreservation); (2) produce a sufficient number of mature oocytes to allow for a meaningful number of embryos to biopsy (typically a minimum of 3–5 blastocysts is desirable to maximise the chance of identifying at least one normal embryo); (3) for PGT-M, have a confirmed molecular diagnosis in the family with the specific mutation identified; and (4) be willing to undergo genetic counselling prior to testing.</p><h3>Who May Not Be Suitable</h3><p>PGT may not be appropriate for patients with very poor ovarian reserve (likely to produce very few embryos, leaving no viable embryo after testing), patients who object to embryo biopsy on ethical or religious grounds, or situations where the mutation in the family has not been identified at a molecular level. In these cases, alternatives such as prenatal diagnosis or gamete donation should be discussed.</p>

<p>The testing approach used during PGT depends on the clinical indication. Significant advances in molecular biology over the past decade have dramatically improved accuracy, turnaround time, and the range of conditions that can be tested.</p><h3>Biopsy Techniques</h3><p><strong>Trophectoderm biopsy (day 5–6):</strong> Currently the preferred approach. A laser is used to create an opening in the zona pellucida, and 4–8 cells from the trophectoderm (future placenta) are aspirated. This provides more DNA for analysis and is associated with lower rates of embryo damage compared to earlier-stage biopsies. Embryos are typically vitrified (flash-frozen) after biopsy and transferred in a subsequent frozen embryo transfer (FET) cycle after results are available. <strong>Cleavage-stage biopsy (day 3):</strong> Historically common but largely superseded; involves removing 1–2 blastomeres from an 8-cell embryo. Higher risk of mosaicism confounding results and possible embryo compromise. <strong>Polar body biopsy:</strong> Samples the first and/or second polar body (discarded cell by-products of egg maturation) to infer the genetic status of the oocyte. Only provides information about the maternal genetic contribution; less widely used.</p><h3>Genetic Analysis Technologies</h3><p><strong>Next-Generation Sequencing (NGS):</strong> The current gold standard for PGT-A and increasingly for PGT-SR. Sequences millions of DNA fragments simultaneously, providing high-resolution copy number analysis of all 23 chromosome pairs. Can detect segmental aneuploidies (gains or losses of chromosome segments), and some platforms detect mosaicism (embryos with a mixture of normal and abnormal cells). <strong>Array Comparative Genomic Hybridisation (aCGH):</strong> Previously the most common platform; compares fluorescent intensity between test and reference DNA across the genome. Largely replaced by NGS in most centres. <strong>Quantitative PCR (qPCR):</strong> Rapid, targeted method that can confirm specific chromosomal copy numbers. Less comprehensive than NGS but faster (4–6 hours). <strong>Single Nucleotide Polymorphism (SNP) Arrays:</strong> Detects specific SNP patterns across the genome; can identify uniparental disomy and triploidy in addition to aneuploidy. Karyomapping (a form of SNP linkage analysis) is widely used for PGT-M. <strong>PCR-based mutation-specific assays:</strong> For PGT-M, custom PCR assays targeting the specific familial mutation combined with simultaneous chromosome analysis (using NGS or SNP) constitute the most robust approach. Each test is validated over several months before clinical use.</p><h3>Mosaic Embryos</h3><p>Advances in NGS sensitivity have revealed that a substantial proportion of embryos are "mosaic" — containing a mix of chromosomally normal and abnormal cells. Current ESHRE and PGDIS guidelines provide a tiered approach: high-level mosaics are generally not recommended for transfer; low-level mosaics may be considered for transfer when no euploid embryos are available, with extensive counselling. Transfer of low-level mosaic embryos has resulted in healthy live births, suggesting that some mosaicism detected at biopsy may not affect the inner cell mass (future fetus).</p>

<p>When used in appropriate clinical contexts, PGT confers several well-documented benefits over IVF without genetic testing:</p><h3>Reduced Miscarriage Risk</h3><p>Chromosomal aneuploidy accounts for approximately 50–60% of all first-trimester miscarriages. By selecting only euploid (chromosomally normal) embryos for transfer, PGT-A significantly reduces pregnancy loss rates. Multiple studies demonstrate miscarriage rates of less than 10% following euploid embryo transfer, compared with 15–25% in unscreened IVF cycles and up to 50% in women over 40 undergoing standard IVF.</p><h3>Improved Implantation and Live Birth Rates Per Transfer</h3><p>Euploid embryos transferred after PGT-A achieve implantation rates of 60–70% per transfer across most published series. A large RCT (STAR trial) showed that PGT-A improved ongoing pregnancy rates per transfer compared with morphology-based selection in women of advanced maternal age. This efficiency can reduce the total number of IVF cycles and embryo transfers needed to achieve a live birth, decreasing physical and emotional burden.</p><h3>Near-Elimination of the Transmitted Genetic Disease Risk</h3><p>For couples who carry a serious single-gene disorder (e.g., cystic fibrosis, Huntington's disease, BRCA1/2 mutations), PGT-M reduces the risk of having an affected child from 25–50% (depending on inheritance pattern) to less than 1–2%, accounting for the small technical error rate. This is transformative for families who have previously experienced an affected child or who are unwilling to consider termination of an affected naturally conceived pregnancy.</p><h3>Psychological Benefits</h3><p>Knowing that transferred embryos have been screened provides significant reassurance for many couples, especially those who have experienced recurrent miscarriage or who are at risk for transmitting a serious hereditary condition. This psychological benefit — while difficult to quantify — is consistently reported as meaningful in patient satisfaction surveys.</p><h3>Potential to Reduce Multiple Pregnancy Risk</h3><p>Because PGT-A allows confident selection of a single high-quality euploid embryo, it supports single embryo transfer (SET) policies, reducing the risk of twin or higher-order multiple pregnancies — which carry substantial maternal and neonatal risks.</p><h3>Preservation of Option to Decline Termination</h3><p>For couples who morally object to terminating an affected pregnancy following prenatal diagnosis, PGT allows them to avoid placing themselves in that position while still conceiving with IVF.</p>

<p>PGT is a sophisticated and largely safe procedure, but several technical limitations and potential risks must be understood before proceeding:</p><h3>Technical Error Rate (Misdiagnosis)</h3><p>No genetic test is 100% accurate. PGT-A error rates with modern NGS platforms are estimated at less than 1–2%, but misclassification of a euploid embryo as aneuploid (or vice versa) can occur. For PGT-M, the technically validated diagnostic error rate is typically reported as less than 1%, but allele dropout and contamination remain theoretical risks. This is why confirmatory prenatal testing (amniocentesis or CVS) is routinely recommended after a successful pregnancy is established following PGT-M.</p><h3>Embryo Damage During Biopsy</h3><p>Although modern trophectoderm biopsy is considered safe for the embryo, there is a small procedural risk of embryo damage or loss during biopsy (estimated 0.1–0.5%). Day-3 cleavage-stage biopsy carries higher risk. The overall risk to a blastocyst from trophectoderm biopsy combined with vitrification is low in experienced laboratories.</p><h3>Mosaicism Interpretation</h3><p>The detection of chromosomal mosaicism creates diagnostic uncertainty. A mosaic result does not always reflect the true chromosomal status of the inner cell mass, and current understanding of clinical outcomes following mosaic embryo transfer remains evolving. Genetic counselling is essential when mosaicism is detected.</p><h3>No Euploid Embryos Available</h3><p>A significant proportion of couples — particularly those of advanced maternal age or poor ovarian reserve — may complete an IVF+PGT cycle and find that no euploid embryos are available for transfer. This outcome, while informative, is emotionally devastating. Before starting, realistic counselling about this possibility is essential.</p><h3>Does Not Screen for All Conditions</h3><p>PGT-A cannot detect single-gene mutations (unless PGT-M is specifically added), structural birth defects that occur normally in chromosomally normal embryos, or de novo mutations arising after biopsy. PGT-M only tests for the specific pre-identified familial mutation; it does not provide a comprehensive genomic screen for all possible conditions.</p><h3>Ethical Considerations</h3><p>PGT involves the creation and potential non-transfer (or discard) of embryos, which raises ethical concerns for some individuals and communities. Sex selection using PGT for non-medical reasons is prohibited in many countries. Use of PGT-HLA for "saviour siblings" and PGT for late-onset conditions (e.g., BRCA2, Huntington's disease with variable penetrance) requires careful ethical deliberation. Genetic counselling by a qualified counsellor before starting PGT is considered mandatory best practice.</p><h3>Cost and Access</h3><p>PGT adds substantial cost to an IVF cycle. Not all health insurance plans cover PGT, and access varies significantly by country. Patients should verify coverage before initiating treatment.</p>

<p>After a successful embryo transfer following PGT, ongoing monitoring and follow-up are essential to confirm pregnancy, detect any complications, and ensure optimal maternal and fetal outcomes.</p><h3>Post-Transfer Monitoring (First 2 Weeks)</h3><p>Approximately 10–14 days after embryo transfer, a serum beta-hCG (human chorionic gonadotrophin) blood test is performed to confirm biochemical pregnancy. If positive, a repeat beta-hCG is taken 48–72 hours later to confirm appropriate doubling, indicating a viable early pregnancy. Progesterone supplementation (vaginal pessaries, gels, or intramuscular injections) is continued throughout the luteal phase and typically until 10–12 weeks of gestation in frozen embryo transfer cycles.</p><h3>Early Pregnancy Ultrasound</h3><p>A transvaginal ultrasound is typically performed at 6–7 weeks of gestation to confirm an intrauterine pregnancy and fetal cardiac activity. A further scan at 8–10 weeks confirms ongoing viability before transfer of care to an obstetric provider.</p><h3>Confirmatory Prenatal Diagnosis</h3><p>For pregnancies established following PGT-M, ESHRE guidelines and most specialist centres strongly recommend confirmatory prenatal diagnosis via <strong>chorionic villus sampling (CVS)</strong> at 10–13 weeks or <strong>amniocentesis</strong> at 15–18 weeks. Although the residual risk of error is very low (<1%), confirmatory testing provides additional reassurance and may detect rare technical errors or de novo mutations unrelated to the tested condition. For PGT-A, non-invasive prenatal testing (NIPT) on maternal blood from 10 weeks is an option, though it is not equivalent to invasive diagnostic testing.</p><h3>Standard Obstetric Care</h3><p>From 12 weeks onward, obstetric care follows standard protocols, including first-trimester combined screening, anatomy scan at 18–20 weeks, gestational diabetes screening, and any additional surveillance warranted by maternal age or obstetric risk factors. IVF-conceived pregnancies are monitored with slightly greater vigilance due to modestly higher rates of preterm birth and low birth weight compared to spontaneously conceived pregnancies, though absolute risk remains low.</p><h3>Unused Embryos</h3><p>Any vitrified embryos not transferred in the current cycle remain in cryostorage. Couples must decide on the long-term fate of these embryos — future transfers, continued storage, donation to another couple, donation for research, or compassionate transfer (allowing the embryo to thaw without transfer). This decision should be revisited regularly and documented in advance through a legal consent process with the fertility clinic.</p>

<p>PGT adds meaningful cost to an IVF cycle. The total investment varies considerably based on the type of testing, the number of embryos, the technology platform used, and geography.</p><h3>Cost Breakdown</h3><p><strong>IVF base cycle cost:</strong> USD $10,000–$15,000 in the USA; £5,000–£8,000 in the UK; INR 1,50,000–3,00,000 in India; SGD $8,000–$15,000 in Singapore; AUD $8,000–$12,000 in Australia.</p><p><strong>PGT-A (aneuploidy screening):</strong> USD $3,000–$6,000 per cycle (includes biopsy, vitrification, thaw, and NGS analysis for a batch of embryos). Some centres charge per embryo (USD $300–$500/embryo) while others charge a flat cycle fee.</p><p><strong>PGT-M (single-gene disorder):</strong> USD $5,000–$10,000+ per cycle above IVF costs, due to the custom probe/assay design and validation required before the cycle. The design phase itself may cost USD $1,500–$3,000 and takes 6–12 weeks.</p><p><strong>PGT-SR (structural rearrangements):</strong> Comparable to PGT-M pricing due to similar assay design complexity.</p><h3>Factors Influencing Total Cost</h3><ul><li>Number of embryos biopsied (more embryos = higher total lab cost on per-embryo pricing models)</li><li>Technology platform (NGS is typically slightly more expensive than aCGH but more informative)</li><li>Whether a frozen embryo transfer (FET) cycle is billed separately</li><li>Medication costs for controlled ovarian stimulation (USD $3,000–$7,000 in the USA)</li><li>Whether the laboratory is in-house or a send-out reference lab</li><li>Country of treatment: India, Thailand, Spain, and Czech Republic offer significantly lower total costs for medical tourism patients</li><li>Insurance coverage: Some US insurers cover PGT for recurrent pregnancy loss or known genetic carriers under specific plans</li></ul><h3>Insurance and Funding</h3><p>In the UK, NHS funding for PGT-M may be available for couples at high risk of transmitting a serious inherited condition, subject to regional commissioning decisions. In the USA, insurance coverage is highly variable by state and employer plan. In Australia, Medicare provides partial rebates for IVF but PGT is typically self-funded. Patients in countries with limited funding often travel to Spain, Czech Republic, Cyprus, or India for PGT-IVF cycles at a fraction of the domestic cost while maintaining comparable laboratory standards.</p>

<p>PGT is one of several strategies available to couples wishing to have a child unaffected by a known genetic condition or chromosomal abnormality. The most appropriate choice depends on the specific indication, patient values, ethical considerations, financial resources, and medical history.</p><h3>Prenatal Diagnosis (PND)</h3><p>The traditional approach involves conceiving naturally (or with IVF without PGT) and then testing the fetus during pregnancy through <strong>chorionic villus sampling (CVS)</strong> at 10–13 weeks or <strong>amniocentesis</strong> at 15–18 weeks. Both provide definitive chromosomal and genetic diagnosis. However, these invasive tests carry a small risk of procedure-related miscarriage (approximately 0.5–1%), and if an affected fetus is detected, the couple must decide whether to continue or terminate the pregnancy — a decision that many couples find deeply distressing. PGT avoids this dilemma by testing before implantation.</p><h3>Non-Invasive Prenatal Testing (NIPT)</h3><p>NIPT analyses cell-free fetal DNA in maternal blood from 10 weeks of gestation and can detect the most common aneuploidies (Trisomies 21, 18, 13; sex chromosome aneuploidies) with high sensitivity and specificity. However, NIPT is a screening test — not a diagnostic test — and does not replace CVS or amniocentesis for definitive diagnosis. It cannot detect single-gene mutations (except in a limited and expensive expanded NIPT panel).</p><h3>Gamete Donation</h3><p>Couples where one partner carries an autosomal dominant condition may choose to use donor sperm or donor eggs (depending on which partner is affected), thereby eliminating the risk of transmission without the need for PGT. This option avoids embryo biopsy but means the child will not be genetically related to one parent.</p><h3>Natural Conception With Acceptance of Risk</h3><p>Some couples, particularly those with lower-penetrance conditions or strong ethical/religious objections to IVF, choose to conceive naturally and rely on prenatal screening or choose not to test. Genetic counselling helps them understand the per-pregnancy risk and make an informed decision.</p><h3>Adoption or Foster Care</h3><p>For couples who do not wish to pursue IVF or testing, adoption or fostering provides a route to parenthood. This is not a medical alternative but is a meaningful life choice that genetic counsellors may discuss alongside medical options.</p><p>The decision between PGT and its alternatives is deeply personal and should be made with the support of a reproductive endocrinologist, clinical geneticist, and genetic counsellor who can present a balanced view of all options.</p>